Samsung Biologics reports Q4, 2021 fiscal year financial results

By The Science Advisory Board staff writers

January 25, 2022 -- Samsung Biologics reported strong financial results for the fourth quarter and record high earnings for the 2021 fiscal year, achieving fourth quarter revenue of 444.3 billion South Korean won ($37 million U.S.), an increase of 18% from 375.3 billion South Korean won ($31 billion U.S.) reported for the fourth quarter last year.

The company's fourth quarter 2021 operating profit was 128.8 billion South Korean won ($11 million U.S.), which was 39% higher than the prior year period. Meanwhile, the company's fourth quarter 2021 net profit reached 79.3 billion South Korean won ($66 million U.S.), a decrease of 16.9 billion South Korean won ($14.1 million U.S.) from 96.2 billion South Korean won ($77 million U.S.) in the fourth quarter a year ago. The fourth quarter 2021 operating margin was 29% due to increased utilization across all plants and improved product mix, Samsung said.

Samsung Biologics demonstrated strong operational and business agility in 2021 with its three manufacturing plants in stable operations, the firm said. With its mRNA business, it signed strategic partnership agreements with Moderna for fill and finish and Greenlight Biosciences for the manufacturing of mRNA vaccines. Samsung Biologics also launched its newest contract development organization process platform, S-Cellerate, for the development and commercialization of monoclonal antibodies.


Copyright © 2022 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here